ArticleBlood2024
Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.
Qi Jin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleBlood2024
Qi Jin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.